Per Capita Antibiotic Consumption: How Does a North American Jurisdiction Compare with Europe?

Authors / Contributors:
[David M. Patrick, Fawziah Marra, James Hutchinson, Dominique L Monnet, Helen Ng, William R. Bowie]
Place, publisher, year:
2004
Contained in:
Clinical Infectious Diseases, 39/1(2004-07-01), 11-17
Format:
Article (online)
ID: 400145405
LEADER caa a22 4500
001 400145405
003 CHVBK
005 20180310124831.0
007 cr unu---uuuuu
008 161202e20040701xx s 000 0 eng
024 7 0 |a 10.1086/420825  |2 doi 
035 |a (NATIONALLICENCE)oxford-10.1086/420825 
245 0 0 |a Per Capita Antibiotic Consumption: How Does a North American Jurisdiction Compare with Europe?  |h [Elektronische Daten]  |c [David M. Patrick, Fawziah Marra, James Hutchinson, Dominique L Monnet, Helen Ng, William R. Bowie] 
520 3 |a Antibiotic consumption in populations affects the emergence of resistant organisms. We compared 1996-2000 trends in consumption in British Columbia, Canada, with those in Europe. Prescription data from the British Columbia PharmaNet database were converted into SAS files and classified using the Anatomical Therapeutic Chemical system, and weights of antibiotics were converted into defined daily doses (DDDs) using the 2001 definitions from the World Health Organization Collaborating Center for Drug Statistics Methodology. During 1996-2000, consumption in British Columbia decreased from 19.5 to 17.9 DDDs/1000 inhabitant-days. Although antibiotic consumption in British Columbia was less than the European median in 2000, it exceeded that in northern European countries with established antibiotic surveillance and control programs. The consumption rates for fluoroquinolones, newer macrolides, and cephalosporins in British Columbia exceeded those in Denmark (1.44 vs. 0.15, 1.59 vs. 0.92, and 1.86 vs. 0.02 DDDs/1000 inhabitant-days, respectively). The observed increase in and pattern of consumption associated with newer antimicrobials may increase the risk for emergence of antimicrobial-resistant organisms in British Columbia. 
540 |a © 2004 Infectious Diseases Society of America 
700 1 |a Patrick  |D David M.  |u Centre for Disease Control, Vancouver  |4 aut 
700 1 |a Marra  |D Fawziah  |u Centre for Disease Control, Vancouver  |4 aut 
700 1 |a Hutchinson  |D James  |u Department of Medicine, Memorial University, St. John's, Newfoundland, Canada  |4 aut 
700 1 |a Monnet  |D Dominique L.  |u Statens Serum Institut, Copenhagen, Denmark  |4 aut 
700 1 |a Ng  |D Helen  |u Centre for Disease Control, Vancouver  |4 aut 
700 1 |a Bowie  |D William R.  |u Department of Medicine, University of British Columbia, Vancouver  |4 aut 
773 0 |t Clinical Infectious Diseases  |d The University of Chicago Press  |g 39/1(2004-07-01), 11-17  |x 1058-4838  |q 39:1<11  |1 2004  |2 39  |o cid 
856 4 0 |u https://doi.org/10.1086/420825  |q text/html  |z Onlinezugriff via DOI 
908 |D 1  |a research-article  |2 jats 
950 |B NATIONALLICENCE  |P 856  |E 40  |u https://doi.org/10.1086/420825  |q text/html  |z Onlinezugriff via DOI 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Patrick  |D David M.  |u Centre for Disease Control, Vancouver  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Marra  |D Fawziah  |u Centre for Disease Control, Vancouver  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Hutchinson  |D James  |u Department of Medicine, Memorial University, St. John's, Newfoundland, Canada  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Monnet  |D Dominique L.  |u Statens Serum Institut, Copenhagen, Denmark  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Ng  |D Helen  |u Centre for Disease Control, Vancouver  |4 aut 
950 |B NATIONALLICENCE  |P 700  |E 1-  |a Bowie  |D William R.  |u Department of Medicine, University of British Columbia, Vancouver  |4 aut 
950 |B NATIONALLICENCE  |P 773  |E 0-  |t Clinical Infectious Diseases  |d The University of Chicago Press  |g 39/1(2004-07-01), 11-17  |x 1058-4838  |q 39:1<11  |1 2004  |2 39  |o cid 
900 7 |a Metadata rights reserved  |b CC BY-NC-4.0  |u http://creativecommons.org/licenses/by-nc/4.0  |2 nationallicence 
898 |a BK010053  |b XK010053  |c XK010000 
949 |B NATIONALLICENCE  |F NATIONALLICENCE  |b NL-oxford